OverviewSuggest Edit

Royal DSM is a science-based company engaged in nutrition, health, and sustainable living. The company delivers business solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. It operates through three segments: Nutrition, Materials, and Innovation Center. The Nutrition segment provides solutions for animal feed, food & beverages, pharmaceuticals, early life nutrition, nutrition improvement, dietary supplements, and personal care. The Materials segment provides fiber solutions, high-performance plastics, resins solutions. The Innovation Center segment develops biomedical, solar, and bio-based products and services.
TypePublic
Founded1902
HQHeerlen, NL
Websitedsm.com
Employee Ratings4
Overall CultureF

Latest Updates

Employees (est.) (Mar 2020)21,866(-1%)
Job Openings305
Revenue (FY, 2018)€9.3 B(+8%)
Share Price (Sept 2021)€185.2
Cybersecurity ratingBMore

Key People/Management at Royal DSM

Rob Routs

Rob Routs

Chairman
Geraldine Matchett

Geraldine Matchett

Co-CEO & CFO
Dimitri de Vreeze

Dimitri de Vreeze

Co-CEO & COO
Marcus Remmers

Marcus Remmers

Chief Technology Officer
Koen Janssen

Koen Janssen

Vice President, Innovation, RT&D & Sustainability, Biomedical
Marc Hendriks

Marc Hendriks

VP Strategy and Business Development
Show more

Royal DSM Office Locations

Royal DSM has offices in Heerlen, Amsterdam, Delft, Emmen and in 171 other locations
Heerlen, NL (HQ)
1 Het Overloon
Amsterdam, NL
Strawinskylaan 1
Delft, NL
1 Alexander Fleminglaan
Delft, NL
Turbineweg 10
Emmen, NL
Eerste Bokslootweg 17
Geleen, NL
Koestraat 1
Show all (186)

Royal DSM Financials and Metrics

Royal DSM Revenue

Embed Graph
View revenue for all periods
Royal DSM's revenue was reported to be €9.27 b in FY, 2018 which is a 7.4% increase from the previous period.
EUR

Revenue (Q3, 2019)

2.3b

Net income (Q3, 2019)

239.0m

EBITDA (Q3, 2019)

416.0m

EBIT (Q3, 2019)

266.0m

Market capitalization (15-Sept-2021)

31.2b

Closing stock price (15-Sept-2021)

185.2

Cash (30-Sept-2019)

926.0m

EV

32.9b
Royal DSM's current market capitalization is €31.2 b.
Annual
EURFY, 2016FY, 2017FY, 2018

Revenue

7.9b8.6b9.3b

Revenue growth, %

(11%)9%7%

Cost of goods sold

5.3b5.7b5.9b

Gross profit

2.7b2.9b3.4b
Quarterly
Annual
EURFY, 2016FY, 2017FY, 2018

Cash

604.0m899.0m1.3b

Accounts Receivable

1.5b1.5b1.6b

Inventories

1.8b1.8b2.0b

Current Assets

5.0b5.4b6.3b
Quarterly
EURQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

574.0m369.0m1.6b1.1b813.0m997.0m1.0b1.1b926.0m

Accounts Receivable

1.6b1.6b1.6b1.8b1.8b1.7b1.8b1.7b1.7b

Inventories

1.9b1.9b1.8b1.9b2.0b2.0b2.1b2.1b2.1b

Current Assets

5.2b5.2b6.3b6.0b5.8b5.9b6.6b6.3b5.8b
Annual
EURFY, 2016FY, 2017FY, 2018

Net Income

629.0m1.8b1.1b

Depreciation and Amortization

489.0m502.0m509.0m

Inventories

(138.0m)(201.0m)(166.0m)

Accounts Payable

195.0m127.0m(6.0m)
Quarterly
EURQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash From Operating Activities

196.0m329.0m619.0m310.0m503.0m933.0m201.0m507.0m941.0m

Capital Expenditures

(130.0m)(250.0m)(384.0m)(172.0m)(319.0m)(470.0m)(150.0m)(269.0m)(420.0m)

Cash From Investing Activities

(194.0m)(268.0m)906.0m(143.0m)(364.0m)(505.0m)(474.0m)(331.0m)(364.0m)

Long-term Borrowings

(4.0m)(25.0m)(12.0m)(57.0m)(340.0m)
EURFY, 2016

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x

P/E Ratio

2.1
Show all financial metrics

Royal DSM Operating Metrics

FY, 2016FY, 2017FY, 2018

Countries (Facilities)

404040

Manufacturing Facilities

100100110

Patent Applications Filed Yearly

220282397

Suppliers

40 k34 k35 k
Show all operating metrics

Royal DSM Acquisitions / Subsidiaries

Company NameDateDeal Size
SRF LimitedMay 13, 2019₹3.2 b
Amyris Brasil Pesquisa e DesenvolvimentoDecember 29, 2017
Biocare Copenhagen ApSDecember 22, 2017
TwilmijSeptember 22, 2017
Suzhou Sunshine New Materials Technology Co LtdFebruary 16, 2017
Cubic Tech CorpMay 13, 2015
Aland (Jiangsu) NutraceuticalMarch 31, 2015
Bayer - Animal Health Premix BusinessJuly 02, 2013
Unitech Industries LtdJune 28, 2013
FortitechDecember 18, 2012$634 m
Show more

Royal DSM Revenue Breakdown

Embed Graph

Royal DSM revenue breakdown by business segment: 31.4% from Materials, 66.2% from Nutrition and 2.3% from Other

Royal DSM revenue breakdown by geographic segment: 9.8% from Rest of Asia, 12.2% from China, 11.7% from Latin America, 6.4% from Eastern Europe, 22.3% from North America, 24.1% from Rest of Western Europe and 13.5% from Other

Human Capital Metrics

Royal DSM's employees are reported to be approximately 28% female and 72% male.
Embed Graph
Show all human capital metrics

Royal DSM Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Royal DSM Online and Social Media Presence

Embed Graph

Royal DSM Company Culture

  • Overall Culture

    F

    44/100

  • CEO Rating

    F

    15/100

  • Compensation

    D

    55/100

Learn more on Comparably

Royal DSM News and Updates

Ørsted signs power purchase agreement with Royal DSM

Royal DSM will purchase renewable electricity from Ørsted to meet the North America requirements as part of its global GHG emission reduction.

Global Medical Composites Markets to 2025 Featuring 3M, Toray Industries, CeramTec, Dentsply Sirona, Royal DSM, & SGL Carbon

DUBLIN, May 25, 2021 /PRNewswire/ -- The "Medical Composites Market by Fiber Type(Carbon and Ceramic), Application (Diagnostic Imaging, Composite Body Implants, Surgical Instruments, and Dental), and Region (Europe, North America, APAC, Latin America, and MEA) - Global Forecast to 2025"...

Worldwide UV Coating Industry to 2024 - Featuring Akzonobel, Royal DSM & PPG Industries Among Others

Dublin, Oct. 02, 2020 (GLOBE NEWSWIRE) -- The "UV Coating Market 2019-2024: Trends, Forecast, and Opportunity Analysis" report has been added to ResearchAndMarkets.com's offering. The future of the UV coating market looks promising with opportunities in the industrial coating, electronics, and g…

Nutraceutical Ingredients Market Outlook, 2025 Featuring Royal DSM, DuPont, Cargill, ADM, BASF, Omega Protein Corp

DUBLIN, July 12, 2019 /PRNewswire/ -- The "Global Nutraceutical Ingredients Market by Type, by Products, by Region - Market Outlook 2025" report has been added to ResearchAndMarkets.com's offering. Global nutraceutical market has witnessed a slowdown in mergers and acquisition activities...

Royal DSM Boosts 2019 Outlook

Royal DSM Boosts 2019 Outlook

Informative Report on Medical Device Coatings Market 209 | Key Players like Surmodics, Inc., Covalon Technologies Ltd., Royal DSM, Hydromer. Inc., Precision Coatings Co. Inc., AST Products Inc.

Medical coatings range from lubrications to anti-microbial liquids to water repellent polymers, and each variety of coating is used on a multitude of devices for many different applications. Medical equipment is used at every phase of procedure, from basic check-ups, as well to surgeries and clinica…
Show more

Royal DSM Frequently Asked Questions

  • When was Royal DSM founded?

    Royal DSM was founded in 1902.

  • Who are Royal DSM key executives?

    Royal DSM's key executives are Rob Routs, Geraldine Matchett and Dimitri de Vreeze.

  • How many employees does Royal DSM have?

    Royal DSM has 21,866 employees.

  • What is Royal DSM revenue?

    Latest Royal DSM annual revenue is €9.3 b.

  • What is Royal DSM revenue per employee?

    Latest Royal DSM revenue per employee is €423.8 k.

  • Who are Royal DSM competitors?

    Competitors of Royal DSM include Nestle, FrieslandCampina and Lonza.

  • Where is Royal DSM headquarters?

    Royal DSM headquarters is located at 1 Het Overloon, Heerlen.

  • Where are Royal DSM offices?

    Royal DSM has offices in Heerlen, Amsterdam, Delft, Emmen and in 171 other locations.

  • How many offices does Royal DSM have?

    Royal DSM has 186 offices.